Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SCYNEXIS INC entered into License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK) valued at $90 million (effective 2023-03-30).
- Action
- entry
- Agreement
- license
- Counterparty
- GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK)
- Value
- $90 million
- Effective
- 2023-03-30
Exact text from the filing
On March 30, 2023 SCYNEXIS, Inc. entered into a license agreement (the “License Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SCYNEXIS INC amended First Amendment and Consent to Loan and Security Agreement with Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A. valued at approximately $35.4 million.
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A.
- Value
- approximately $35.4 million
Exact text from the filing
In connection with the entering into of the License Agreement, SCYNEXIS entered into a First Amendment and Consent to Loan and Security Agreement with the Lenders pursuant to which the Lenders consented to SCYNEXIS entering into the License Agreement and SCYNEXIS agreed to pay to the Lenders an amount equal to the sum of (i) all outstanding principal plus all accrued and unpaid interest with respect to the amounts loaned under the Loan Agreement (approximately $35.4 million), (ii) the prepayment fee payable under Loan Agreement ($262,500), (iii) the final payment payable under Loan Agreement ($1,382,500), and (iv) all other sums, if any, that shall have become due and payable with respect to loan advances under the Loan Agreement.
View on SEC.gov